Formulation and Stability Study of Omeprazole Oral Liquid Suspension for Pediatric Patients

被引:11
|
作者
Boscolo, Oriana [1 ]
Perra, Francesco [1 ,2 ]
Salvo, Leandro [1 ]
Buontempo, Fabian [1 ,3 ]
Lucangioli, Silvia [1 ,4 ]
机构
[1] Univ Buenos Aires, Buenos Aires, DF, Argentina
[2] Univ Cagliari, Cagliari, Italy
[3] Hosp Pediat JP Garrahan, Buenos Aires, DF, Argentina
[4] Consejo Nacl Invest Cient & Tecn, Buenos Aires, DF, Argentina
关键词
omeprazole; formulation; stability study; pediatric; acid-related diseases; PROTON PUMP INHIBITORS;
D O I
10.1177/0018578719844704
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives:To develop and to study the physicochemical and microbiological stability of omeprazole liquid oral formulations used as therapeutic agent in many acid-related disorders, for pediatric use. Furthermore, to optimize and validate a stability-indicating high-performance liquid chromatography (HPLC) method for the analysis of omeprazole in the studied formulations.Method:Oral liquid suspensions of omeprazole were prepared at 2 mg/mL using crushed omeprazole pellets (formulation A) and pure omeprazole (formulation B) with a complete vehicle including humectant, suspending, sweetening, antioxidant, and flavoring agents. Samples were stored at 4 degrees C and 25 degrees C. Omeprazole content of each formulation was analyzed in triplicate using micro-HPLC at 0, 3, 7, 14, 30, 60, 90, 120, and 150 days. Other parameters were also determined, such as appearance, pH, resuspendibility, and viscosity. Microbiological studies were conducted according to the United Stated Pharmacopeia (USP) guidelines for non-sterile products.Results:Formulation A stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions during at least 150 days and it only stayed stable during 14 days at 25 degrees C. Formulation B was stayed physicochemical and microbiologically stable at refrigerated (4 degrees C) conditions at least 90 days, but it is not recommended to store at 25 degrees C for more than 1 day.Conclusions:Formulation A and formulation B can be stored for at least 150 and 90 days, respectively, at refrigerated conditions. Formulation A can be stored at room temperature for 14 days. Both formulations are perfectly suitable for pediatric patients who are usually notable to swallow solid oral formulations. The proposed analytical method was suitable for the study of stability of different formulations.
引用
收藏
页码:314 / 322
页数:9
相关论文
共 50 条
  • [21] FORMULATION OF A CIMETIDINE ORAL SUSPENSION
    TORTORICI, MP
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1979, 36 (01): : 22 - 22
  • [22] Bioequivalence Study With Lapatinib Powder for Oral Suspension and the Original Tablet Formulation in Cancer Patients
    Koch, Kevin M.
    Ferron-Brady, Geraldine
    Lemmon, Colleen
    Cartee, Leanne
    Hollyfield, Hedy
    D'Amelio, Anthony M., Jr.
    Piepszak, Alexandra
    Swaby, Ramona F.
    Curran, David
    Arya, Niki
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (03): : 203 - 209
  • [23] Comparative Stability of Compounded Omeprazole Suspension Versus Commercial Omeprazole Kit When Stored in Oral Syringes Under Refrigerated Conditions
    Jackson, Remonica
    Lewis, Paul
    Brown, Stacy D.
    JOURNAL OF PHARMACY TECHNOLOGY, 2020, 36 (05) : 179 - 186
  • [24] Stability of suspension formulations of lansoprazole and omeprazole stored in amber-colored plastic oral syringes
    DiGiacinto, JL
    Olsen, KM
    Bergman, KL
    Hole, EB
    ANNALS OF PHARMACOTHERAPY, 2000, 34 (05) : 600 - 605
  • [25] Formulation and stability of an extemporaneously compounded propafenone hydrochloride oral suspension for children with arrhythmia
    Lin, Yi-Shiu
    Lin, Shu-Chiao
    Hsieh, Ya-Ting
    Liu, Ling-Yu
    Lin, Chiu-Hsin
    Shen, Li-Jiuan
    Huang, Chih-Fen
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2022, 29 (06) : 324 - 328
  • [26] Design and stability study of an oral solution of amlodipine besylate for pediatric patients
    van der Vossen, A. C.
    van der Velde, I.
    Smeets, O. S. N. M.
    Postma, D. J.
    Vermes, A.
    Koch, B. C. P.
    Vulto, A. G.
    Hanff, L. M.
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2016, 92 : 220 - 223
  • [27] Amlodipine in pediatric patient with uncontrolled multifactorial hypertension. Formulation of amlodipine oral suspension
    Lago Rivero, N.
    Arias Santos, I.
    Paradela Carreiro, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2012, 16 (08) : 1117 - 1119
  • [28] First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation
    Mauro Morri
    Patricia Castellano
    Darío Leonardi
    Silvana Vignaduzzo
    AAPS PharmSciTech, 2018, 19 : 1781 - 1788
  • [29] Interaction between liquid protein solution and omeprazole suspension
    Freeman, Kevin L.
    Trezevant, May S.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2009, 66 (21) : 1901 - 1902
  • [30] First Development, Optimization, and Stability Control of a Pediatric Oral Atenolol Formulation
    Morri, Mauro
    Castellano, Patricia
    Leonardi, Dario
    Vignaduzzo, Silvana
    AAPS PHARMSCITECH, 2018, 19 (04): : 1781 - 1788